全球梅毒螺旋體檢測市場 - 市場規模（按細分市場）、份額、監管、報銷、預測（~2033）

梅毒疫情的上升和社會意識的提高是梅毒檢測市場的主要成長動力。 市場上也出現了各種新型梅毒診斷設備和檢測平台，近年來創新新產品的推出和監管部門的批准有所增加。 還需要進行梅毒診斷的即時 (POC) 檢測，因為實驗室檢測非常耗時，並且可能導致治療延誤。

這些診斷測試可快速提供結果，縮短住院時間並立即做出治療決定。 血清學檢測是最廣泛使用的梅毒檢測。 梅毒可在懷孕期間引起嚴重的併發症，包括非免疫性胎兒水腫、子宮內生長受限、自然流產、早產和圍產兒死亡，以及受感染的活產嬰兒的嚴重後遺症。 在許多國家，對所有婦女在懷孕前三個月進行篩檢被認為是一種具有成本效益的策略。

本報告研究和分析了全球梅毒螺旋體檢測市場，並提供了有關每個細分市場的市場規模、市場趨勢、競爭格局以及 COVID-19 影響的資訊。

市場模型的主要內容如下。

已上市的梅毒螺旋體檢測和不斷變化的競爭格局

• 對主要產業趨勢的考慮
• 梅毒螺旋體檢測市場年收入與市場前景（按細分市場）（2015-2033 年）
• 有關單位數量、平均售價和市場價值的市場級數據

全球、區域和國家層面的特定市場考量

• 按地區細分全球趨勢的特定市場定性資訊和國家/地區考慮因素
• 梅毒螺旋體檢測市場的SWOT分析
• 梅毒螺旋體檢測市場競爭動態的考量與趨勢

透過對醫療保健系統的真實、全面的了解來促進市場了解。 市場進入部分還提供有關報銷政策和監管環境的信息，使您能夠更深入地研究市場動態。

• 各國醫療保健系統概覽
• 按國家/地區劃分的報銷政策
• 各國醫療科技監理狀況

目標公司

• Illumina Inc
• BGI Genomics Co Ltd
• Yourgene Health Plc
• Eurofins Scientific SE
• Agilent Technologies Inc
• F. Hoffmann-La Roche Ltd
• Revvity Inc
• Danaher Corp
• Abbott Laboratories
• Siemens AG
• Quidelortho Corp
• Thermo Fisher Scientific Inc
• Tosoh Corp
• 其他

Abstract

Treponema Pallidum Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on Treponema Pallidum Tests market for the year 2020 and beyond. Syphilis is a type of sexually transmitted disease which can lead to long-term health complications if left untreated. Treponema pallidum is the causative organism of the syphilis. The increasing prevalence of syphilis as well as growing public awareness represent major driving factors for growth of the syphilis testing market. The market is also witnessing various new syphilis diagnostic devices and testing platforms, with an increased number of product launches and regulatory approvals occurring in recent years for new and innovative products. There is also a demand for point of care (POC) tests for syphilis diagnosis, due to the time-consuming process of laboratory-based tests that can lead to treatment delays.

These diagnostic tests provide rapid results, reduce hospital stays and lead to immediate treatment decisions. Serological tests represent the most widely used form of Syphilis testing. Syphilis can cause serious complications in pregnancy and result in non-immune hydrops fetalis, intrauterine growth restriction, spontaneous abortion, preterm delivery, and perinatal death as well as serious sequelae in liveborn infected children. Screening of all women in the first trimester of pregnancy is considered a cost-effective strategy in many countries.

The Treponema Pallidum Tests include Venereal Disease Research Laboratory (VDRL), Rapid Plasma Reagin (RPR), Unheated Serum Reagin (USR), Treponema Passive Particle Agglutination (TPPA), Treponema Pallidum Hemagglutination (TPHA), Fluorescent Treponemal Antibody Absorption (FTA-ABS) and Treponema Pallidum EIA tests.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Treponema Pallidum Tests and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total Treponema Pallidum Tests market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Treponema Pallidum Tests market.
• Competitive dynamics insights and trends provided for Treponema Pallidum Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Becton Dickinson and Co, Abbott Laboratories, Siemens AG, Bio-Rad Laboratories Inc, H.U. Group Holdings Inc, Trinity Biotech Plc, Arlington Scientific Inc, F. Hoffmann-La Roche Ltd, Tecan Group Ltd, Revvity Inc, Cardinal Health Inc, bioMerieux SA, DiaSorin SpA, Omega Diagnostics Group Plc, Rapid Labs Ltd, Deben Diagnostics Ltd, Lorne Laboratories Ltd, Werfen Life Group SAU, Sekisui Diagnostics LLC, and others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the Treponema Pallidum Tests market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Understand the impact of COVID-19 on Treponema Pallidum Tests market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Treponema Pallidum Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Treponema Pallidum Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Track device sales in the global and country-specific Treponema Pallidum Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Not Applicable

List of Tables

Not Applicable

List of Figures

Not Applicable